文献速递认知障碍与痴呆帕金森病与运动障碍

血浆P-Tau217与NfL在神经退行性疾病中的纵向变化:α-突触核蛋白对阿尔茨海默病的影响

Plasma P-Tau217 and NfL Longitudinal Changes Across Neurodegenerative Diseases: Impact of α-Synuclein in Alzheimer Disease.
PubMed 文献 · Neurology · 2026-11-02

这项前瞻性单中心队列研究纳入223例认知障碍患者,随访36个月,分析血浆p-tau217和NfL的纵向变化。结果显示AD患者p-tau217随时间增加,且合并α-突触核蛋白病理者增加更陡;FTD和AD-aSyn+的NfL最高,提示更重轴突损伤。

要点

  • AD-aSyn+组血浆p-tau217 36个月增加最陡(2.19 pg/mL,p<0.001)。
  • FTD与AD-aSyn+的NfL基线及随访均最高(均p<0.001)。
  • α-突触核蛋白阳性可识别p-tau217和NfL增加更快的AD亚组。

核心结论

  • 血浆p-tau217在AD中随时间变化,其轨迹受α-突触核蛋白病理调节。
  • AD-aSyn+患者NfL水平更高,与FTD相似,提示更重神经轴突损伤。

研究设计与样本

  • 前瞻性单中心队列,2019至2022年从西班牙巴塞罗那记忆门诊招募223例认知障碍患者。
  • 纳入标准为神经退行性或非神经退行性认知障碍且具备基线和3年随访血样。
  • 基线用Lumipulse检测CSF AD生物标志物,用RT-QuIC评估α-突触核蛋白病理。
  • 基线及36个月用Lumipulse检测血浆p-tau217和NfL,线性混合效应模型分析组间纵向差异。

主要发现

  • 基线血浆p-tau217在AD-aSyn+和AD-aSyn-组最高,DLB-AD+居中,DLB-AD-、FTD和NNCI最低。
  • 36个月内AD-aSyn+的p-tau217增加最陡(2.19 pg/mL;p<0.001),AD-aSyn-和DLB-AD+增加较小,DLB-AD-、FTD和NNCI保持稳定。
  • NfL在FTD和AD-aSyn+基线与随访均最高(均p<0.001),且增加相似;AD-aSyn-、DLB-AD+和DLB-AD-居中并中度增加,NNCI变化有限。

关键数值与推荐

  • AD-aSyn+组p-tau217 36个月增加2.19 pg/mL(p<0.001)。
  • FTD和AD-aSyn+的NfL在基线和随访均最高(均p<0.001)。
  • 共纳入223例:AD-aSyn- 92例,AD-aSyn+ 15例,DLB-AD- 17例,DLB-AD+ 13例,FTD 48例,NNCI 38例。

临床怎么用

  • 血浆p-tau217和NfL纵向轨迹可用于AD进展监测。
  • α-突触核蛋白病理状态有助于识别p-tau217和NfL增加更快的AD亚组。
  • 生物标志物分层可能支持预后判断和临床试验富集。

局限性

  • 单中心研究,样本量有限,尤其AD-aSyn+和DLB亚组例数少。
  • 随访36个月,长期轨迹未明。
  • α-突触核蛋白病理仅用RT-QuIC评估,可能存在错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Plasma phospho-tau217 (p-tau 217) is a validated biomarker of Alzheimer disease (AD), and its longitudinal dynamics may reflect AD progression. Plasma neurofilament light chain (NfL) reflects axonal injury and neurodegeneration. Their trajectories may be modulated by concomitant proteinopathies such as α-synuclein (aSyn). We aimed to characterize longitudinal changes (36 months) in plasma p-tau217 and NfL across neurodegenerative and non-neurodegenerative cognitive disorders and to examine biomarker trajectories according to aSyn pathology status within AD. METHODS: In this prospective single-center cohort, participants were recruited from a memory clinic in Barcelona, Spain. Participants were eligible if they had cognitive impairment because of neurodegenerative or non-neurodegenerative conditions between 2019 and 2022 and if baseline and 3-year follow-up blood samples were available. CSF AD biomarkers measured with Lumipulse and aSyn pathology assessed using real-time quaking-induced conversion assay were determined at baseline and used for patient diagnosis. Plasma p-tau217 and NfL were measured with Lumipulse at baseline and 36 months and analyzed as study outcomes. Between-group differences at longitudinal level were assessed using linear mixed-effects models. RESULTS: A total of 223 participants were included: 92 AD-aSyn- (69.6 [5.6] years, 57.8% female), 15 AD-aSyn+ (69.1 [5.8] years, 53.3% female), 17 dementia with Lewy bodies (DLB)-AD- (70.9 [6.8] years, 23.5% female), 13 DLB-AD+ (age 72.3 [5.0] years, 30.8% female), 48 frontotemporal lobar dementia (FTD) (65.5 [8.8] years, 45.8% female), and 38 non-neurodegenerative cognitive impairment (NNCI) (65.3 [7.7] years, 35.9% female). At baseline, AD-aSyn+ and AD-aSyn- groups showed the highest plasma p-tau217, whereas DLB-AD+ showed intermediate levels and DLB-AD-, FTD, and NNCI the lowest. Over 36 months, AD-aSyn+ exhibited the steepest increase in p-tau217 (2.19 pg/mL; p < 0.001), whereas AD-aSyn- and DLB-AD+ showed smaller increases; DLB-AD-, FTD, and NNCI remained stable. For NfL, FTD and AD-aSyn+ had the highest levels at baseline and follow-up (both p < 0.001), with similar increases. AD-aSyn-, DLB-AD+, and DLB-AD- showed intermediate values with moderate increases, whereas NNCI displayed limited changes. DISCUSSION: Plasma p-tau217 changes longitudinally in AD, and its trajectory is modulated by α-synuclein pathology. Patients with AD-aSyn+ show higher levels of NfL, similar to FTD, highlighting greater neuroaxonal injury. α-synuclein positivity identifies an AD-aSyn+ subgroup with steeper increases in p-tau217 and NfL, supporting biomarker-based stratification for prognosis and trial enrichment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Esteller-Gauxax D, Pérez-Millan A, Sarto J, et al. Plasma P-Tau217 and NfL Longitudinal Changes Across Neurodegenerative Diseases: Impact of α-Synuclein in Alzheimer Disease. Neurology. 2026. PMID: 42970748. doi:10.1212/WNL.0000000000218685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。